3-(Boc-氨基)-3-苯基丙酸 | 14676-01-8

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: 3-(Boc-氨基)-3-苯基丙酸
• 中文别名: 3-(叔丁氧基羰基氨基)-3-苯丙酸；3-(叔丁氧羰基氨基)-3-苯基丙酸
• 英文名称: 3-(tert-butoxycarbonylamino)-3-phenylpropanoic acid
• 英文别名: 3-(Boc-amino)-3-phenylpropionic acid；3-(N-tert-butoxycarbonylamino)-3-phenyl-DL-propionic acid；3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid
• CAS: 14676-01-8
• 化学式: C₁₄H₁₉NO₄
• mdl: MFCD02090695
• 分子量: 265.309
• InChiKey: JTNQFJPZRTURSI-UHFFFAOYSA-N

物化性质

• 熔点：
  186 °C
• 沸点：
  329.46°C (rough estimate)
• 密度：
  1.158
• 稳定性/保质期：

  在常温常压下稳定，应避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S24/25
• 危险类别码：
  R22
• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P301+P312,P302+P352,P304+P340,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Name:	3-Benzylaminobutyric Acid 98% Material Safety Data Sheet
Synonym:	None Known
CAS:	14676-01-8

Section 1 - Chemical Product MSDS Name:3-Benzylaminobutyric Acid 98% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
14676-01-8	3-Benzylaminobutyric Acid	98%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam. Use agent most appropriate to extinguish fire.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 14676-01-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystals
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 186 - 188 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: soluble in water
Specific Gravity/Density:
Molecular Formula: C6H5CH2NHCH(CH3)CH2COOH
Molecular Weight: 193.1105

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 14676-01-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Benzylaminobutyric Acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 14676-01-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 14676-01-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 14676-01-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(Boc-氨基)-3-苯基丙酸 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.75h， 生成 DL-3-氨基-3-苯基丙酸
  参考文献：
  名称：

  衍生自具有抗HIV活性的α-，β-和γ-氨基酸的2,2'-二硫代双苯甲酰胺：合成与构效关系。

  摘要：

  含有高度保守的逆转录病毒锌指的核衣壳蛋白（NCp7）在人类免疫缺陷病毒（HIV）生命周期的早期和晚期都是必不可少的，并且是AIDS治疗的新目标。HIV-1 NCp7是基本的55个氨基酸氨基酸蛋白，在两侧各含两个C（X）2C（X）4H（X）4C基序锌指。先前已报道2,2'-二硫代双苯甲酰胺从这些NCp7锌指中释放锌，并抑制HIV复制。具体而言，衍生自简单氨基酸的2,2'-二硫代双苯甲酰胺显示出良好的抗病毒活性。苯并异噻唑酮3（2的环状衍生物）被选为临床试验中的艾滋病治疗剂。本文中我们报告了2,2'的合成和抗病毒活性，包括治疗指数 衍生自α-，β-和γ-氨基酸的β-二硫代双苯甲酰胺。电喷雾电离质谱法用于研究这些化合物的锌喷射活性。在α-氨基酸衍生的2,2'-二硫代双苯甲酰胺中，发现含有烷基侧链的类似物具有良好的治疗指数，具有抗病毒活性。发现衍生自β-和γ-氨基酸的2,2'-二硫代双苯甲酰胺比α

  DOI：

  10.1016/s0968-0896(98)00118-7
• 作为产物：
  描述：

  benzohydroximoyl chloride 在 ruthenium trichloride 、 sodium periodate 、 lithium aluminium tetrahydride 、 乙基溴化镁 、 potassium carbonate 作用下， 以 四氢呋喃 、 四氯化碳 、 乙醚 、 二氯甲烷 、 异丙醇 、 乙腈 为溶剂， 生成 3-(Boc-氨基)-3-苯基丙酸
  参考文献：
  名称：

  A Concise Approach to Structurally Diverse β-Amino Acids

  摘要：

  We have demonstrated that the high yields and selectivities of 1,3-dipolar cycloadditions can be translated into facile stereoselective syntheses of a diverse array of beta-amino acids, key components of bioactive natural products, beta-lactams, and peptidomimetics. Simply by selecting different combinations of three readily available starting materials (an oxime, a chiral allylic alcohol, and a nucleophile), we used the reaction sequence to prepare four different beta-amino acid structural types with a variety of substitution patterns in good overall yield. Of particular note is the use of this approach to prepare highly substituted beta-amino acids not readily accessible by previously reported methodologies. This will pave the way for future studies of the structure and function of this important class of molecules.

  DOI：

  10.1021/ja0298747

文献信息

• [EN] WNT PATHWAY ANTAGONISTS<br/>[FR] ANTAGONISTES DE LA VOIE WNT
  申请人：SIENA BIOTECH SPA

  公开号：WO2011042145A1

  公开（公告）日：2011-04-14

  The present invention relates to known and novel compounds of formula (I) as herein described and pharmaceutical compositions thereof. The compounds of formula (I) have inhibitory effect on the Wnt pathway and are therefore useful in the preparation of a medicament, in particular for the treatment of cancer.

  本发明涉及如下所述的已知和新颖的化合物（I）的公式及其药物组成。公式（I）的化合物对Wnt途径具有抑制作用，因此在制备药物方面特别适用于治疗癌症。
• [EN] GLYT2 MODULATORS<br/>[FR] MODULATEURS DU GLYT2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005044810A1

  公开（公告）日：2005-05-19

  α-, β-, and Ϝ-amino acid derivatives of formula I are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain. Formula I

  公式I的α-, β-, 和 Ϝ-氨基酸衍生物被披露为选择性GlyT2抑制剂，用于治疗中枢神经系统（CNS）疾病，如肌肉痉挛、耳鸣、癫痫和神经痛。
• Thiadiazole amide MMP inhibitors
  申请人：——

  公开号：US05830869A1

  公开（公告）日：1998-11-03

  The present invention provides novel thiadiazole amide derivatives represented by formula I ##STR1## The compounds of the present invention inhibit various enzymes from the matrix metalloproteinase family, predominantly stromelysins, and hence are useful for the treatment of matrix metallo endoproteinase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis, periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation and other diseases related to connective tissue degradation.

  本发明提供了由式I表示的新型噻二唑酰胺衍生物。本发明的化合物抑制来自基质金属蛋白酶家族的各种酶，主要是胶原酶，因此对于治疗基质金属蛋白酶疾病如骨关节炎、类风湿性关节炎、化脓性关节炎、骨质疏松症如骨质疏松症、肿瘤转移、牙周炎、牙龈炎、角膜溃疡、皮肤溃疡、胃溃疡、炎症和其他与结缔组织降解相关的疾病具有用处。
• Modifications of Peptides by Chelate Claisen Rearrangements of Manganese Enolates
  作者：Sabine Maier、Uli Kazmaier

  DOI：10.1002/1099-0690(200004)2000:7<1241::aid-ejoc1241>3.0.co;2-u

  日期：2000.4

  Deprotonation of allylic esters of peptides at -70 °C in the presence of metal salts results in the formation of metal peptide enolate complexes, which undergo Claisen rearrangement on warming to room temperature to produce stereoselectively modified peptides. By far the best results are obtained with manganese enolates. With these enolates, the amino acids incorporated in the peptide chain have no

  在金属盐存在下在-70°C下使肽的烯丙基酯去质子化，导致形成金属肽烯醇化物络合物，该化合物在升温至室温后进行克莱森重排，产生立体选择性修饰的肽。到目前为止，用烯醇锰盐可获得最佳结果。对于这些烯醇化物，掺入肽链中的氨基酸对重排无明显影响，对产量和立体化学结果均无影响。因此，该方案非常适合通过使用手性烯丙基醇的酯对肽进行立体选择性修饰。α-烷基化氨基酸也可以掺入肽中。
• [EN] PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS À BASE D'ACIDE GAMMA-HYDROXYBUTYRIQUE, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
  申请人：XW LAB INC

  公开号：WO2017049470A1

  公开（公告）日：2017-03-30

  The present application discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.

  本申请公开了γ-羟基丁酸的前药，以及其组合物和用途。